Nabil Chehab, Lung Cancer Medical Franchise Head/Executive Medical Director-US Medical Affairs at AstraZeneca, shared on LinkedIn:
“What’s the key to ensuring longer term survival for people facing lung cancer?
Preventive screening.
The American Lung Cancer Association reported today that while five-year survival has risen to 31%, less than 25% of eligible high-risk people receive low-dose CT screening.
When lung cancer is detected in its early stages, patients have access more treatment options and experience better health outcomes.
At AstraZeneca, we believe that closing those healthcare disparities is critical to our mission of eliminating cancer as a cause of death.
We’ve partnered with advocacy groups and policymakers nationwide to connecting at-risk communities to early interventions, including education, screening and biomarker testing.
Through our LungHealth, Unified program, we’ve been building coalitions and infrastructure needed to translate awareness into sustained action across five states with low screening rates.
A few 2026 highlights include:
- Activating the Healthy Lungs California Advocacy and Policy Collaborative and advanced the Stop Lung Cancer Early Act, and expanded lung health priorities.
- Building a stakeholder network in Florida around lung cancer screening, biomarker testing and COPD.
- Funding community-based lung cancer screening in Kentucky’s underserved areas.
- Establishing Maryland’s Lung Health Collaborative to drive lung care and health equity initiatives.
- Launching the Lone Star Lung Alliance in Texas, which promoted lung health issues with policymakers and stakeholders to build legislative momentum.
And we’ll keep going in 2027, collaborating in communities all over the U.S. to serve patients where they live.
Our team is committed to supporting people from screening and diagnosis through treatment and survival, centered on the principle that every patient deserves the best care no matter their zip code.
You can learn more about LungHealth, Unified here: LungHealth Unified.”
You can also read:
Sandhya Sapra Joins AstraZeneca as Lung Tumor Lead for Oncology Outcomes Research
National Study Confirms Impact of NHS Lung Cancer Screening Programme – The Royal Marsden.
Nikolaos A. Dallas: LiveWell Helps Us Build a More Accessible Lung Cancer Screening Pathway.